A considerable roadblock in the successful triaging of new therapeutics for liver and metabolic related diseases is the reliability and effectiveness of pre-clinical disease models. Methods employing animal models may…

ICON, a healthcare intelligence and clinical research organisation, with the US Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the US…

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win technology platform, has announced data from a pre-defined interim analysis related to the lung cohort…

…trials, most notably in oncology and autoimmune disease. “Rabies represents an ideal opportunity to provide rapid clinical validation of our novel vaccine technology given the large exposure-naïve population and established…

…discovery times of relevant peptide leads based on affinity screens and/or functional screens. Orano Med will focus on subsequent development of the peptides for clinical use after conjugation with lead-212….

…clinical development and commercialisation of cancer vaccines and TCER therapeutics resulting from the collaboration. Immatics will be responsible for conducting the preclinical studies and a potential Phase I clinical trial…

…metastatic urothelial cancer patients. J Clin Med. 2022;11(15): 4483. Montazeri K & Bellmunt J. Erdafitinib for the treatment of metastatic bladder cancer. Expert Review of Clinical Pharmacology. 2020;13(1):1-6. https://classic.clinicaltrials.gov/ct2/show/NCT03390504 https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-metastatic-bladder-cancer…

…Phase II trial evaluating the clinical efficacy of a six-month treatment with temelimab on the improvement of cognitive impairment and/or fatigue in Long Covid patients who are positive for the…

A considerable roadblock in the successful triaging of new therapeutics for liver and metabolic related diseases is the reliability and effectiveness of pre-clinical disease models. Methods employing animal models may…

…Clinical Trials, under identifier Ariceum SSO11O-01. Manfred Rüdiger, Chief Executive Officer of Ariceum Therapeutics, said: “The initiation of this Phase Ib study is an important milestone reached by the company…

The first quadruplex-edited, allogeneic CAR-T cell therapy candidate has entered clinical trials in the US. The first patient has been treated with Beam Therapeutics’ BEAM-201 as part of a Phase…

…Applications to regulators have included pre-clinical data showing that the Omicron XBB.1.5-adapted monovalent Covid-19 vaccine generates a substantially improved response against multiple XBB-related sublineages, including XBB.1.5, XBB.1.16, and XBB.2.3, compared…

…help companies meet these new regulations quickly and effectively. Using data to improve inclusion in clinical trials brings us a step closer to a clinical development industry that benefits all…

…the bottlenecks for its impact. We hope that our system will generate a platform of transformative, and economically viable approaches to clinical problems that remain poorly addressed in modern medicine.”…

…study marks a significant milestone in treating this complex disease and serves as the leading asset in our clinical development portfolio. BEN-8744 exemplifies our innovative approach targeting a novel pathway…

A considerable roadblock in the successful triaging of new therapeutics for liver and metabolic related diseases is the reliability and effectiveness of pre-clinical disease models. Methods employing animal models may…